It activates amylin and calcitonin receptors in the hypothalamus
Unapproved peptides, however, are a different story
It's also worth noting the gap between manufacturer direct-to-consumer pricing and standard retail cash pricing at the same pharmacy chain can be substantial as of mid-2026, a standard cash-pay box of Wegovy at a typical retail pharmacy still runs well above $1,300, compared with the $349 manufacturer-direct price for the same drug through NovoCare Pharmacy [4]
Thats a meaningful signal but heres what it does NOT mean: it does not mean these peptides are approved for compounding yet
Injection-Site and Administration Differences Both peptides are administered subcutaneously in clinical practice, though AOD-9604 was also tested orally
Both terms refer to the same GLOW pre-mixed single-vial composition of GHK-Cu, BPC-157, and TB-4